Degradable hydrogel microparticles for controlled hydrophobic ingredient release
VeraMorph's degradable hydrogel microparticles offer a customizable solution for encapsulating and releasing hydrophobic ingredients in aqueous environments. Utilizing DPOD technology, these microparticles provide efficient loading and controlled release, suitable for various applications.
Overview
VeraMorph introduces an innovative solution for the controlled release of hydrophobic active ingredients using degradable hydrogel microparticles. These microparticles encapsulate up to 60% by weight of active ingredient(s), with a customizable release profile ranging from 30 minutes to several months. The technology is based on the DPOD (dissociating polymeric oral dosage) system, originally developed for pharmaceuticals, which can now be adapted for broader applications. The hydrogels decompose into biocompatible polymers, ensuring environmental safety and biocompatibility.
Technical specifications
Key features:
- Encapsulation efficiency exceeding 90% for hydrophobic ingredients
- Customizable release profiles by adjusting polymer chemistry and microstructure
- Biocompatible and environmentally degradable polymers
- Compatibility with over three dozen active pharmaceutical ingredients (APIs)
- Demonstrated ability to improve API solubility in water by over 1000 times
The microparticles are manufactured by swelling hydrogels with an active ingredient solution, then removing the solvent, allowing for precise control over the encapsulation process.
Technology readiness level
This technology is currently at Technology Readiness Level 4. It has been validated in laboratory settings, showing potential for adaptation to extended release applications. Future validation steps include in-vitro release and biodegradation studies to characterize material performance for a range of active ingredients. VeraMorph is actively seeking partners to support further development, scale-up, and validation efforts.
About VeraMorph
VeraMorph is a specialty pharmaceutical company that has developed a proprietary, environmentally-responsive oral drug delivery platform known as DPOD (Dissociated Polymeric Oral Dosages). This technology utilizes a unique mechanism of action where a cross-linked hydrogel structure transforms into individual polymers that are released alongside drug nanoparticles. By improving the solubility and stabilization of poorly soluble drug substances without chemical modification, the platform aims to enhance the clinical efficacy and therapeutic potential of both novel compounds and existing approved medications. VeraMorph’s approach is designed to be highly compatible across a broad range of drug properties and is scalable for efficient development.
The company focuses on maximizing therapeutic efficacy and patient outcomes by developing a portfolio of clinically-differentiated oral versions of approved drugs and out-licensing its platform technology to pharmaceutical partners. A key application is the development of an oral formulation of fulvestrant for metastatic breast cancer, which seeks to replace the standard, painful monthly intramuscular injections with a more potent and convenient treatment. By streamlining formulation optimization and clinical translation, VeraMorph aims to reduce the significant time, financial, and clinical risks associated with traditional pharmaceutical R&D, ultimately working to improve the standard of care for various disease indications.
Inquire about this partnering listing
Industry applications
delivered to your inbox.